Mon, Jan 26, 2015, 3:39 AM EST - U.S. Markets open in 5 hrs 51 mins

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

robert.vince 96 posts  |  Last Activity: Jan 23, 2015 7:55 AM Member since: Aug 30, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • robert.vince by robert.vince Nov 19, 2014 6:57 PM Flag

    Must be expecting something big:
    On November 13, 2014, Aethlon Medical, Inc. (the "Company") entered into an Office Lease (the "Lease") with T-C Stonecrest LLC. Pursuant to the Lease, the Company agreed to rent approximately 2,600 square feet of executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego, California 92123 at an initial base rental rate of $6,054 per month. The Lease has a term of 39 months and an estimated commencement date of December 1, 2014, and provides for the rate to increase to a maximum rate of $6,620 per month over the term of the Lease. Notwithstanding the foregoing, the Lease also provides that, so long as the Company is not in default under the Lease, the base rate for months 2, 3 6 and 7 will be partially abated to a rate of $3,027 per month and the base rate for months 13 and 14 will be partially abated to a rate of $3,117 per month.

  • robert.vince by robert.vince Nov 19, 2014 11:32 AM Flag

    With a consistent streak of setting new records in product sales, accelerating adoption of CytoSorb (CTSO), case studies supporting efficacy of the device in several applications and certain near-term catalysts to further expand the already burgeoning commercial footprint, we view this as an opportunistic entry point for investors. We believe CTSO remains highly undervalued and are reiterating our Outperform rating and $0.50/share price target. See below for free access to our updated report and financial model on CTSO.

    CytoSorbents (CTSO) reported results for the third quarter ending September 30, 2014. The streak of setting a new record in product revenue was extended to seven straight quarters with Q3 product revenue coming in at $1.0 million, an increase of 276% and 56% from Q3 2013 (i.e. - yoy) and Q2 2014 (i.e. - sequentially), respectively. Also consistent are the catalysts of the product revenue growth - those being increasing re-order volumes and expansion of the customer base. Sales through Biocon, the company's distributor in India, also were indicated as a particular catalyst in driving product sales in Q3 and which continue to build steam.

    We reiterate, that while there remains the potential for short-term variability in product sales, that we continue to believe that a certain base of business has been established whereby follow-on orders should provide a solid floor. This, coupled with broadening the geographic footprint and customer base - both of which the company has had early successes in doing from internal sales efforts and distribution relationships - should provide for near-to-long term product sales growth and improving operating leverage.

  • Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA expanded access "emergency use" provisions to support requests from qualified physicians and institutes that may seek to treat ebola virus infection in the United States.
    Aethlon previously disclosed that it would provide Hemopurifier® therapy on a humanitarian basis through FDA compassionate use access provisions, which allow for the use of an investigational device to treat an individual patient or small group based on clearance by FDA prior to treatment.

    Based on FDA guidance, Aethlon will now provide Hemopurifier® therapy to treat Ebola infection through expanded access "emergency use" provisions in the United States. Expanded access "emergency use" of an investigational device does not require advance FDA approval for life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.

    The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. In the treatment of Ebola, Aethlon recently announced that Hemopurifier® therapy was administered to Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients. At the time of treatment, which occurred at Frankfurt University Hospital in Germany, the patient was unconscious and suffering from multiple organ failure.

    Sentiment: Strong Buy

  • robert.vince robert.vince Nov 18, 2014 10:35 AM Flag

    Some people wanted to lock in a profit, and some scared they'd lose theirs. Long term believers scooping up, new believers scooping up, probably a bunch of doctors fresh out of the conference scooping up....

  • New York, NY / ACCESSWIRE / November 18, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Aethlon Medical, Inc. (AEMD), a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. In the note, SeeThruEquity is raising its price target price to $0.74 from $0.52.

    "Aethlon Medical's announcement that its Hemopurifier device was used to treat an Ebola patient in Germany is encouraging. We believe the Hemopurifier will be shown to be an advanced, broad-spectrum countermeasure against pandemic threats like Ebola. It is significant that the Chief of Nephrology at Frankfurt University Hospital reported that 242 million Ebola viruses were captured within the Hemopurifier(R) during the treatment, resulting in a 400-fold reduction in viral load. In light of these developments, we are increasing our price target to $0.74 per share," stated Ajay Tandon, Chief Executive Officer of SeeThruEquity.

    The note is available here: AEMD Company Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will also be available on these platforms.

    Highlights from the note are as follows:

  • Reply to

    drop

    by a30fyrs Nov 17, 2014 12:21 PM
    robert.vince robert.vince Nov 18, 2014 4:41 AM Flag

    If you're on scottrade, they're having glitches.

  • Nano cap Aethlon Medical (OTCQB:AEMD +29.8%) jumps on massive turnover of 10M shares in response to its report of the successful treatment of a critically-ill Ebola patient in Germany with its Hemopurifier bio-filtration device. In a post-treatment analysis, the device captured 242M Ebola viruses. The patient is expected to make a full recovery.The Hemopurifier targets the broad-spectrum elimination of viruses and immunosuppressive proteins from the blood.The stock has more than tripled since mid-October when the first treatment with the Hemopurifier was reported.

    Sentiment: Strong Buy

  • Reply to

    SCOTRADE ACTING UP TODAY

    by nelsonsancho Nov 17, 2014 11:06 AM
    robert.vince robert.vince Nov 17, 2014 12:05 PM Flag

    Its doing the same for me. I thought my GPDB went bankrupt. Whew....

  • Reply to

    A little more positive media attention

    by robert.vince Nov 15, 2014 4:28 PM
    robert.vince robert.vince Nov 15, 2014 4:29 PM Flag

    Connor and Franch made their own presentation at the nephrology society’s conference, which was held in Philadelphia. They spoke about their use of kidney dialysis — without the Hemopurifier — on an Ebola patient.

    To prove the Hemopurifier actually removed Ebola viruses from Mawanda’s bloodstream, the device was flushed after the treatment course. Researchers at Philipps University of Marburg — in Marburg, Germany, then measured the virus particles they found. Those researchers said 242 million Ebola viruses were captured by the Hemopurifier, according to Geiger.

    As to the central issue of whether the device can help a patient survive Ebola, that can be determined only by clinical trials, Franch and Connor said.

    It’s questionable whether the Hemopurifier made much of a difference in Mawanda’s case, the physicians said. The device was used late in the course of illness — 12 days after diagnosis. Moreover, the patient’s Ebola viral load was already declining.

    “At its peak, viral load can exceed 10 billion copies per milliliter,” Connor said. “I think it is a stretch to say their patient got better because of this. I expect the patient would have survived and gotten better anyway.”

    Mawanda was still very sick at the time; he was unconscious, suffering multiple organ failure and breathing on a ventilator, said James Joyce, Aethlon’s chairman and chief executive.

    The Hemopurifier can be used with standard dialysis or Continuous Renal Replacement Therapy machines, Joyce said. Mawanda was already undergoing kidney dialysis, so the Hemopurifier was added to his dialysis machine.

  • http://www.utsandiego.com/news/2014/nov/14/aethlon-hemopurifier-ebola/
    Ebola virus level falls after Aethlon treatment
    Nearly all Ebola virus particles were eliminated from the blood of a patient treated with an experimental dialysis device made by Aethlon Medical of San Diego, it was reported Friday at the American Society of Nephrology’s annual meeting.

    The patient, a Ugandan doctor who had treated Ebola patients in Sierra Leone, has recovered from the potentially fatal disease.

    Before treatment with Aethlon’s Hemopurifier, the patient had 400,000 virus particles per milliliter of blood. After the dialysis, which lasted about six and a half hours, the “viral load” dropped to 1,000 per milliliter and never rose above that level again, said Dr. Helmut Geiger. He is chief of nephrology at Frankfurt University Hospital in Germany, where the patient received his Ebola care.

    As with all other Ebola treatments, survival can’t be attributed to the Hemopurifier, said Emory University physicians Michael Connor Jr. and Harold Franch, who have treated Ebola patients and attended Geiger’s presentation Friday.

    The patient in Germany, Michael Mawanda, also received other experimental therapies. So it’s difficult to determine the relative importance of any one treatment, Connor and Franch said.

    Use of the Hemopurifier in this case showed success as a proof of concept, Franch said. The interior of the cylindrical cartridge contains a protein that selectively binds to viral particles and fragments, pulling them out of blood circulation.

    “I think they can rightly claim it does look like the drop in virus was temporally timed with the device, so it’s extremely likely the device works” in the strict sense of filtering out viruses, said Franch, an associate professor of medicine in the university’s division of renal medicine.

    Sentiment: Strong Buy

  • Reply to

    open on monday

    by jbcoopertire Nov 15, 2014 9:28 AM
    robert.vince robert.vince Nov 15, 2014 10:19 AM Flag

    It already hit Foxnews and Time magazine... its needle moving time.

  • http://www.foxnews.com/health/2014/11/14/patient-cured-ebola-in-germany-treated-with-bio-filtration-device/

    Sentiment: Strong Buy

  • robert.vince robert.vince Nov 14, 2014 4:19 PM Flag

    Agreed. Lets put blood filtration on everybody's plate.

  • robert.vince robert.vince Nov 14, 2014 4:09 PM Flag

    Both good companies doing slightly different things, but if you think AEMD is a one trick ebola pony, you are sadly mistaken. It can be used to remove any virus from the blood. They're currently working on Hep C and HIV in addition to cancer exosome removal. AEMD's success can only help CTSO as it brings blood filtration devices to the peoples attention.

  • robert.vince robert.vince Nov 14, 2014 1:07 PM Flag

    Agreed. I'm a long time AEMD shareholder that found out about CTSO from their board. Bought CTSO cause I couldn't figure out which one would be successful, the longer I hold, the more I believe both will. BTW, here is the rest of the news, yahoo has not made posting it easy:
    "The rate of viral load reduction and magnitude of Ebola virus captured within the Hemopurifier® is quite remarkable when considering the lethality of Ebola infection and the compromised health of the patient," stated James A. Joyce, Chairman and CEO of Athlon Medical. "We're thrilled for the patient and applaud the tireless effort of physicians in Frankfurt who helped to save the patient's life. We will continue to advance Hemopurifier® therapy as a lead candidate to address antiviral drug resistance and the sole broad-spectrum strategy to address Ebola other viruses where drugs and vaccines have not proven to be effective."

    Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

  • robert.vince robert.vince Nov 14, 2014 12:54 PM Flag

    Since the administration of Hemopurifier® therapy, Frankfurt University Hospital officials have reported that Ebola virus is no longer detectable in the patient's blood and full recovery is expected.

    "The rate of viral load reduction and magnitude of Ebola virus captured within the Hemopurifier® is quite remarkable when considering the lethality of Ebola infection and the compromised health of the patient," stated James A. Joyce, Chairman and CEO of Athlon Medical. "We're thrilled for the patient and applaud the tireless effort of physicians in Frankfurt who helped to save the patient's life. We will continue to advance Hemopurifier® therapy as a lead candidate to address antiviral drug resistance and the sole broad-spectrum strategy to address Ebola other viruses where drugs and vaccines have not proven to be effective."

    Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV)

    Sentiment: Strong Buy

  • This news is good for CTSO too IMHO
    Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to treat infectious disease, created the Hemopurifier®, a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.

    The Frankfurt University Hospital patient, a Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients, was not administered Hemopurifier® therapy until 12 days after being diagnosed.

    At the time of Hemopurifier® administration, Dr. Geiger reported that the Ebola patient was unconscious and suffering from multiple organ failure, which required mechanical ventilation, continuous dialysis and the administration of vasopressor medications.

    The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported.

    Since the administration of Hemopurifier® therapy, Frankfurt University Hospital officials have reported that Ebola virus is no longer detectable in the patient's blood and full recovery is expected.

    Sentiment: Strong Buy

  • The Aethlon Hemopurifier® was used in the successful treatment of a critically-ill Ebola-infected patient in Frankfurt, Germany, according to data presented today at the American Society of Nephrology (ASN) Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology at Goethe University, Frankfurt University Hospital. Geiger reported that 242 million Ebola viruses were captured within the Aethlon Hemopurifier® during treatment, a number verified by a post-treatment elution protocol. The patient is no longer infected with Ebola virus and is expected to make a full recovery.
    Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to treat infectious disease, created the Hemopurifier®, a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.

    The Frankfurt University Hospital patient, a Ugandan physician, who was infected with Ebola in Sierra Leone where he was treating Ebola patients, was not administered Hemopurifier® therapy until 12 days after being diagnosed.

    At the time of Hemopurifier® administration, Dr. Geiger reported that the Ebola patient was unconscious and suffering from multiple organ failure, which required mechanical ventilation, continuous dialysis and the administration of vasopressor medications.

    The patient's viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. The treatment was well tolerated with no adverse events reported.

  • - CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat critically-ill patients in multiple countries worldwide, announced today the appointment of Alan D. Sobel, CPA to its Board of Directors.
    Al Kraus, Chairman of the Board of Directors of CytoSorbents, commented "We are very pleased to announce the addition of Alan to our Board of Directors. Alan's history of business leadership, financial expertise, and in-depth knowledge of manufacturing organizations will add to the breadth of our current Board of Directors."

    Alan D. Sobel is the Managing Member of Sobel & Co., LLC, a Livingston, NJ based full-service accounting, auditing, taxation, and business consulting firm with a diverse clientele including small and mid-sized businesses, non-profit agencies, SEC-registered companies, and individuals. He has provided corporate advisory and consulting services, including mergers and acquisitions, for clients in the real estate, manufacturing, pharmaceutical, and distribution businesses, amongst others. Alan is a Certified Public Accountant, and has served in various leadership roles including Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants. He earned a Bachelor of Science degree in Accountancy from Bentley College, and a Master of Science in Taxation from Fairleigh Dickinson University.

    Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, commented "In addition to being a member of our Board of Directors, Alan will serve as the Chairperson of our newly-formed Audit Committee, and also will serve as Chairperson of our newly-formed Nominating and Corporate Governance Committee. With his financial expertise and guidance, we feel confident we will have the proper oversight to ensure the adequate functioning of our system of internal controls over financial reporting.

  • Pluristem Therapeutics (NASDAQ:PSTI) CEO Zami Aberman purchased 13,000 shares of Pluristem Therapeutics stock on the open market in a transaction that occurred on Tuesday, November 11th. The stock was purchased at an average cost of $2.64 per share, with a total value of $34,320.00. Following the acquisition, the chief executive officer now directly owns 1,768,298 shares in the company, valued at approximately $4,668,307. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
    Shares of Pluristem Therapeutics (NASDAQ:PSTI) traded up 0.77% on Wednesday, hitting $2.63. 49,391 shares of the company’s stock traded hands. Pluristem Therapeutics has a one year low of $2.53 and a one year high of $4.63. The stock’s 50-day moving average is $2.91 and its 200-day moving average is $3.03. The company’s market cap is $182.2 million.
    Pluristem Therapeutics (NASDAQ:PSTI) last posted its quarterly earnings results on Monday, October 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.04. Analysts expect that Pluristem Therapeutics will post $-0.44 EPS for the current fiscal year.
    Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Pluristem Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Monday, October 6th. They now have a $3.10 price target on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of Pluristem Therapeutics in a research note on Monday, September 22nd. They set an “outperform” rating on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Pluristem Therapeutics from $3.50 to $3.00 in a research note on Monday, September 15th. They now have a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock.

ALNY
93.42+0.250(+0.27%)Jan 23 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.